I am liking what I read about ZOTAL -ZOTAL are the exclusive...

I am liking what I read about ZOTAL -

ZOTAL are the exclusive distributor in Israel for the Zymo Research group who just recently secured CE Mark approval for their SARS-CoV-2 Multiplex Kit:
https://www.nsmedicaldevices.com/news/zymo-research-quick/
https://www.zymoresearch.com/blogs/press-releases/zymo-research-obtains-ce-ivd-mark-for-its-quick-sars-cov-2-multiplex-kit

Sienna Cancer Diagnostics (since merged with BARD1, ASX: BD1) also partnered with ZOTAL back in May for a bladder cancer diagnostic test.
https://www.asx.com.au/asxpdf/20200521/pdf/44j0272pvkmjq2.pdf
https://themarketherald.com.au/sienna-cancer-diagnostics-asxsdx-chooses-zotal-to-distribute-its-htert-device-in-israel-2020-05-21/



From their LinkedIn Page:



Looks like these guys are the right group to carry PromarkerD forward.

Yes big dump from some holders today, perhaps not interested to wait it out any further. I can appreciate that, it is indeed getting a bit frustrating and the lack of news about US efforts is quite disappointing.

RE the post on competition (KidneyIntelX) - they are much further advanced than PIQ in the US but their test is not as accurate as PD.
KidneyIntelX 3,000 cohort study PPV >50% compared to PromarkerD 3,000 cohort study PPV was 74%.


https://www.londonstockexchange.com/news-article/RENX/positive-interim-results-for-validation-study/14140924

Also strange their FDA submission was based on the 1,100 cohort study with slightly higher PPV of 62%



https://www.medrxiv.org/content/10.1101/2020.06.01.20119552v1

Not only do they have a test that is not as accurate as PromarkerD they are also more expensive $950 vs PromarkerD ~$50-150 USD.
They also have no presence outside of the US or CE Mark approval.

So from where I am standing, PIQ is out in front and is the horse I am backing.

As others have said, once we start seeing actual revenue from PromarkerD in our quarterly's we will see significant re-rate.
Fingers crossed Richard and his team don't drop the ball and get carried away in the science of it all and stay focused on the business objectives.